Cancer Symptoms Allow For Diagnosis at Earlier Stages

Diagnosis of cancer in early stages of disease allows for a wider range of effective treatment options and a greater chance for cure. Fortunately, a new study shows that more cancer diagnoses are occurring at early stages, likely due to an increased awareness of cancer symptoms and greater availability of screening programs. The study, published […]

Read More

Head-and-neck-primelines

Overall Survival Benefit for Pembrolizumab in Head and Neck Cancer

In recent years, the standard of care in recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has shifted dramatically. Historically, the chemotherapy and cetuximab containing EXTREME regimen has been the preferred first-line treatment in this setting, though this regimen is associated with high rates of toxicity and can be difficult for patients to […]

Read More

ovarian-cancer-primelines

Is Surgery Appropriate for Patients With Recurrent Ovarian Cancer?

When patients with ovarian cancer develop recurrent disease, secondary surgical cytoreduction followed by platinum-based chemotherapy is a common treatment approach. However, the efficacy of this approach previously has not been verified in a prospective phase III trial. In an attempt to answer that question, the GOG-0213 trial compared secondary cytoreduction followed by chemotherapy to chemotherapy […]

Read More

Regular Aspirin Use Associated With Prolonged Survival for Biliary Tract Cancer

Biliary tract cancer (BTC) is a rare, difficult-to-treat gastrointestinal (GI) cancer that typically presents at late stages and has a poor prognosis. Thoughts are that Aspirin has an anticancer effect due to its anti-inflammatory and anticlotting activities. An analysis recently published in JAMA Oncology evaluated the impact of prolonged aspirin use in 2,934 patients with BTC […]

Read More

Survival Benefit for Induction Chemo in Nasopharyngeal Carcinoma

The majority of patients diagnosed with nasopharyngeal carcinoma are at an advanced stage and have a poor prognosis. Concurrent platinum-based chemotherapy and radiation is currently the standard of care for these patients with high risk, but this treatment is associated with a high rate of relapse. In phase II trials, induction chemotherapy with gemcitabine and […]

Read More

Breast Cancer Risk Increased by Menopausal Hormonal Therapy

Menopausal hormonal therapy (MHT), used to alleviate the symptoms of menopause, has been associated with an increased risk of breast cancer; but findings from previous studies have been inconsistent and lack long-term follow-up. A large, new meta-analysis of published and unpublished sources evaluated 108,647 postmenopausal women, who developed breast cancer, for history of MHT use […]

Read More

ctDNA as a Biomarker of Recurrence and Prognosis in Early-Stage CRC

Adjuvant chemotherapy is standard of care for stage III colorectal cancer (CRC) and high-risk stage II CRC. However, decision making for adjuvant therapy is imperfect and based on risk stratification by stage and clinical risk factors. In recent years, circulating tumor DNA (ctDNA) has emerged as a promising noninvasive and dynamic biomarker for monitoring genomic […]

Read More

Role of Alpelisib in HR-Positive PIK3CA-Mutated Advanced Breast Cancer

The standard of care for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast is endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor. Despite improvements in patient outcomes, a majority of patients eventually develop acquired resistance to endocrine-based therapy that is challenging to treat. […]

Read More